Opinion|Videos|October 22, 2024
68Gallium PSMA-11 PET-CT Imaging vs Conventional Imaging Techniques
Author(s)Oliver Sartor, MD
Key Takeaways
- Gallium PSMA-11 gozetotide is effective in detecting prostate cancer metastases and assessing biochemical recurrence with high sensitivity and specificity.
- The tracer is particularly useful for identifying small lesions and lymph node involvement in prostate cancer patients.
The panelist discusses how 68gallium prostate-specific membrane antigen-11 (PSMA-11) gozetotide is most useful in PET-CT imaging for detecting and staging prostate cancer.
Advertisement
In what situations would you use 68gallium prostate-specific membrane antigen-11 gozetotide in PET-CT imaging? In what situations would this tracer be less useful?
Advertisement
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5